CFTR and cystic fibrosis: In contrast, inflammatory signaling was reduced in monocytes and plasma from patients homozygous for the F508del CFTR trafficking deficient variant, present in 90% of CF patients, treated with ivacaftor/lumacaftor or ivacaftor/tezacaftor (Jarosz-Griffiths et al., 2020).